Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Abstract: The present invention provides for a method to detect and/or quantify a gadolinium-based contrast agents (GBCA) in a sample, the method comprising: (a) providing a sample, (b) contacting the sample with a luminescent agent so that luminescent agent chelates a Gd3+ cation of the GBCA, and (c) measuring quenching of a luminescence emission within a range of wavelength; wherein the quenching of the luminescence emission corresponds to the amount of luminescent agent chelating a Gd3+ cation.

Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Abstract: Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.

Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Abstract: A colorimetric assay of lanthanide or actinide (f-block elements) samples and a sensing construct of functionalized gold nanoparticles are provided. The construct is a gold nanoparticle with hydroxypyridinone ligands on the surface. The colorimetric assay can be performed in two different ways: (1) Gold nanoparticles functionalized with hydroxypyridinone ligands are synthesized, and then added to the sample solution. The presence of f-block elements triggers the gold nanoparticle aggregation, which changes the solution color. (2) Exploiting the competition between Au3+ and cations with higher binding affinities, where the f-block elements quench the nanoparticle growth and affect the color of solution. In both methods, the change in color is used as a sensing principle to quantify the f-block element concentrations in aqueous solutions.

Abstract: Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Abstract: Embodiments relate generally to lanthanide nanocrystals as ultraviolet downconverters.

Abstract: Provided herein are a variety of metal chelators as well as methods of use thereof.

Abstract: Provided herein are separation processes for metal ions present in aqueous solutions based on methods involving liquid-liquid extraction. The separation process involves a chelator that can selectively bind to at least one of the metals at a relatively low pH. This can be used, for example, for recovery and purification of actinides from lanthanides, separation of metal ions based on their valence, and separation of metal ions based on the pH of the extraction conditions.

Abstract: Provided herein are methods for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent to a subject in need of such treatment. The subject can be one who has been, or will be, exposed to one or more known or unknown actinides and/or lanthanides, or a mixture thereof.

Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Abstract: Embodiments relate generally to lanthanide nanocrystals as ultraviolet downconverters.

Abstract: The invention provides for a method for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and a 3,2-HOPO chelating agent to a subject in need of such treatment. The use of both 1,2-HOPO and a 3,2-HOPO chelating agents in combination is more effective than using only one chelating agent alone. The invention is especially useful when practiced on a subject that has been exposed to, have been in contact with, or contaminated by one or more known or unknown actinides and/or lanthanides, or a mixture thereof.